Stephen J. Elledge, PhD is the Gregor Mendel Professor of Genetics and Medicine in the Department of Genetics at Harvard Medical School and the Division of Genetics at the Brigham and Women’s Hospital, and is a Howard Hughes Medical Institute (HHMI) Investigator. He received his B.S. in chemistry from the University of Illinois in 1978 and his Ph.D. in biology from the Massachusetts Institute of Technology in 1983. He began his laboratory at the Baylor College of Medicine in Houston and moved in 2003 to the Brigham and Women’s Hospital and Harvard Medical School Department of Genetics . He is a member of the National Academy of Sciences, National Academy of Medicine, and Americam Academy of Arts and Sciences. He has been the recipient of many awards including the 2010 Dickson Prize, 2013 Lewis S. Rosenstiel Award for Distinguished Work in the Basic Medical Sciences, the 2013 Gairdner Foundation International Award, the 2015 Albert Lasker Basic Medical Research Award, the 2017 Breakthrough Prize in Life Sciences and the 2017 Gruber Prize in Genetics.
Dr. Elledge’s research interests center on the study of proteins that sense and respond to DNA damage, and regulate the cell division cycle and cancer. He has uncovered what is now known as the DNA Damage Response. Along with Dr. Wade Harper, he discovered the two largest families of E3 ubiquitin ligases: the cullin-RING ligases (CRL), starting with the Skp1-Cul1-F-box sub-family, and the RING domain ligases. More recently Dr. Elledge has developed immunological methods, such as VirScan, that allow the genome-wide detection of antiviral antibodies from a single drop of patient blood to determine the history of viral exposure.